Analyst Ratings
Upgrades, downgrades, and price-target changes from Wall Street firms.
Analyst Ratings
Baird Reiterates Buy Rating on Ocular Therapeutix, Inc.
Baird maintains its buy rating for Ocular Therapeutix with a $30 target price.
Analyst Ratings
Baird Reiterates Buy Rating on Jabil Inc.
Baird maintains a positive outlook on Jabil Inc., setting a $440 price target.
Analyst Ratings
Wells Fargo Reiterates Buy Rating on Nucor Corporation
Wells Fargo maintains a buy rating on Nucor with a $283 price target.
Analyst Ratings
Canaccord Genuity Reiterates Buy Rating on Biodesix, Inc.
Canaccord Genuity maintains its buy rating for Biodesix, Inc. with a $27 price target.
Analyst Ratings
Scotiabank Upgrades BXP, Inc. to Buy with $70 Price Target
Scotiabank raises its rating on BXP, Inc. to buy, setting a $70 price target.
Analyst Ratings
Scotiabank Upgrades Essential Properties Realty Trust to 'Buy'
Scotiabank analyst Greg McGinniss raised the rating on Essential Properties Realty Trust to 'buy' with a $33 target.
Analyst Ratings
BMO Capital Reiterates Buy Rating for W. P. Carey Inc.
BMO Capital maintains its buy rating for W. P. Carey Inc. with a target of $84.
Analyst Ratings
Benchmark Reiterates Buy Rating on Sphere Entertainment Co.
Benchmark maintains its buy rating for SPHR, setting a $175 price target.
Analyst Ratings
RBC Capital Reiterates Buy Rating for Praxis Precision Medicines, Inc.
RBC Capital maintains its optimistic outlook with a $449 target for PRAX.
Analyst Ratings
Scotiabank Reiterates Buy Rating on American Healthcare REIT
Scotiabank maintains its buy rating on American Healthcare REIT with a $51 price target.
Analyst Ratings
Raymond James Reiterates Buy Rating on Jabil Inc. (NYSE:JBL)
Raymond James maintains its buy rating on Jabil Inc. with a $450 price target.
Analyst Ratings
RBC Capital Reiterates Buy Rating for Jack Henry & Associates
RBC Capital maintains its buy rating on Jack Henry & Associates, setting a price target of $173.
Analyst Ratings
Scotiabank Reiterates Sell Rating on Camden Property Trust
Scotiabank maintains its sell rating for Camden Property Trust, setting a $102 price target.
Analyst Ratings
HC Wainwright Downgrades TRAW to Hold
HC Wainwright has lowered its rating on TRAW to hold, setting a new price target.
Analyst Ratings
Mizuho Reiterates Buy Rating on Duke Energy
Mizuho maintains its buy rating on Duke Energy with a $135 price target.
Analyst Ratings
Keybanc Reiterates Buy Rating on Arista Networks
Analyst Brandon Nispel maintains a buy rating with a $200 price target for Arista Networks.
Analyst Ratings
Keybanc Reiterates Buy Rating on Marvell Technology
Analyst John Vinh maintains a bullish outlook with a $385 price target.
Analyst Ratings
Wells Fargo Reiterates Buy Rating on Steel Dynamics, Inc.
Wells Fargo maintains its positive outlook on Steel Dynamics with a reiterated buy rating and a $291 price target.
Analyst Ratings
Barclays Reiterates Buy Rating on Indivior Pharmaceuticals
Barclays maintains its bullish outlook on Indivior with a $46 target.
Analyst Ratings
Cantor Fitzgerald Reiterates Buy Rating on Atrium Therapeutics
Cantor Fitzgerald maintains its optimistic view on Atrium Therapeutics with a $25 price target.
Analyst Ratings
Lake Street Reiterates Buy Rating on Smith & Wesson Brands, Inc.
Lake Street maintains a buy rating for Smith & Wesson with a $16.5 price target.
Analyst Ratings
DA Davidson Upgrades NICE Ltd. to Buy, Sets New Price Target
On June 18, 2026, DA Davidson upgraded NICE Ltd. to a buy rating with a $110 price target.
Analyst Ratings
UBS Downgrades Jefferies Financial Group to Hold
UBS analyst Michael Brown lowers Jefferies Financial Group rating to hold, setting a $67 price target.
Analyst Ratings
Baird Reiterates Buy Rating for CarMax, Inc.
Baird analyst Craig Kennison maintains a Buy rating on CarMax with a $55 target.